Preliminary Assessment of [18F]BL40 in PET/CT Scans

Multiple Myeloma Clinical Trial

Official title:

A Phase 1/2 Study to Evaluate the in Vivo Biodistribution, Radiation Dosimetry and a Preliminary Assessment of the Diagnostic Performance of [18F]BL40

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06224309
• Other study ID #: H23-03813
• Status: Not yet recruiting
• Start date: May 2024
• Est. completion date: October 2025

Study information

• Verified date: January 2024
• Source: British Columbia Cancer Agency
• Contact: Pav Ravi
• Phone: 6048776000
• Email: pavithraa.ravi[@]bccancer.bc.ca
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor function. There is a need for novel tracers to image CXCR4-expressing tumors for better detection, staging, and monitoring of aggressive cancers without the need for invasive biopsy procedures that may not always properly capture the extent of a patient's disease.

This study looks to assess the safety and efficacy of a novel radiopharmaceutical known as 18F-BL40 through its use in a PET/CT scan. Participants will receive 2 PET/CT scans:

18F-BL40 and 18F-FDG as part of this study.

Description:

This is a prospective registry study to evaluate the diagnostic utility of 18F-BL40 PET/CT to stage patients with CXCR4-expressing tumors, localize sites of tumors and assess safety and biodistribution of this drug in PET/CT scans.

Each subject will receive two PET/CT scans, one using 18F-BL40 and the other using 18F-FDG. The 18F-BL40 radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.

Follow-up assessments: All subjects will be contacted by phone the day after the injection of 18F-BL40. The subjects will be asked if they experienced any undesirable effects during the 18-72 hours after the administration of 18F-BL40. The local site attending nuclear medicine physician will then make an assessment as to whether these effects are likely related to 18F-BL40 administration.

All subjects will be followed for at least 6 months following the 18F-BL40 PET/CT exam. The evaluation will include a chart review of available imaging, laboratory tests, and treatment. The data required can be obtained from a review of the patient's paper and electronic charts, supplemented by telephone contact as needed to complete the information.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: October 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Age =19 years

2. Life expectancy =3 months

3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

4. Participants with newly diagnosed or documented recurrent malignancy with one of the following cancers:

• Diffuse large B-Cell lymphoma

• Multiple myeloma

• Mantle cell lymphoma

• Marginal zone lymphoma

• Chronic lymphocytic leukemia/small cell lymphoma

• Waldenström Macroglobulinemia

5. For all indications except multiple myeloma, the participants at the time of enrolment must either be at initial presentation with histologically confirmed lymphoma, or have the presence of measurable disease by computed tomography (CT) and/or magnetic resonance imaging (MRI) or at least one visualized lesion on positron emission tomography (PET)/CT imaging (from an [18F]FDG PET) within 60 days of enrolment. In the case of participants with multiple myeloma, there must be documented relapse or progressive disease by MRI or [18F]FDG PET/CT imaging, or measurable disease within 60 days of enrolment (serum M-protein =0.5 g/dL or urine Bence-Jones protein =200 mg/24 hours).

Exclusion Criteria:

1. Pregnant or breast-feeding

2. Medically unstable (e.g., acute illness, unstable vital signs)

3. Unable to lie supine for the duration of imaging

4. Unable to provide written consent

5. Exceeds safe weight limit of the PET/CT bed (204.5 kg) or unable to fit through the PET/CT bore (diameter 70 cm)

6. Participants with widespread liver metastases occupying more than 50% of the liver volume will not be eligible to participate in this study as this would preclude assessment of normal liver activity for dosimetry purposes.

7. Participants who have received chemotherapy or dexamethasone (> 4 mg/day) within 3 weeks or antibody therapy within 6 weeks prior to the [18F]BL40 or [18F]FDG PET/CT scans.

8. Participants who have received radiotherapy in the previous 6 weeks prior to [18F]BL40 or [18F]FDG PET/CT scans to sites of measurable active disease.

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Leukemia, Lymphocytic, Chronic, B-Cell
• Lymphoma
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Mantle-Cell
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Multiple Myeloma
• Waldenstrom Macroglobulinemia
• Waldenström Macroglobulinemia

Intervention

Diagnostic Test:
• 18F-BL40 PET/CT
Vital signs will be recorded prior to the BL40 injection. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the 18F-BL40 from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
• 18F-FDG PET/CT
The patient will return on another day for the 18F-FDG PET/CT scan. A fasting period of 6 hours is required before this scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.
• Routine Blood Draw - Phase 1 only
Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after 18F-BL40 administration.

Locations

Country	Name	City	State
Canada	BC Cancer	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
British Columbia Cancer Agency

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the tolerability of [18F]BL40	Occurrence of dose-limiting toxicities (DLTs) per protocol.	1 hour post injection, 2 hours post injection and 18-72 hours post injection
Primary	To determine the Absorbed doses (ADs) to normal organs and tumors per unit of administered activity of [18F]BL40	Absorbed doses (ADs) to organs and tumors per unit of administered activity is measured in units Gy/MBq.; (Tumor, individual organ dose and whole-body effective dose)	6 months
Primary	To evaluate the proportion of participants with tumors shown by [18F]BL40 PET/CT	Proportion of patients with [18F]BL40 positive disease at core reading.	1 year
Primary	To determine Time Integrated Activity Coefficients for organ and tumor for [18F]BL40	Average time the activity spends in the organ or tumor, measured in units MBq·h/MBq	6 months
Primary	To determine the safety of [18F]BL40	Proportion of subjects with adverse events (AEs), Grade 3 or above AEs, drug-related AEs	1 hour post injection, 2 hours post injection and 18-72 hours post injection
Secondary	The proportion of patients in whom [18F]BL40 and [18F]FDG detect disease	The proportion of patients in whom one or more target lesions are detected by the core readers	1 year
Secondary	To compare the number of lesions identified in [18F]BL40 and [18F]FDG	Scan features for comparison may include, but are not limited to: Total number of lesions detected	1 year
Secondary	To assess tumour detectability and image quality by means of standardised uptake values (SUV) for tumour lesions in [18F]BL40 compared to 2[18F]FDG PET/CT (SUVmax, SUVpeak, tumour to background ratio for liver, blood, and lung, contrast to noise ratio)	Standard Uptake Values (SUV); mean SUV; maximum SUV; peak SUV; Tumor tissue to Background tissue ratio, Tumor/blood; Tumor/Liver; Tumor/ kidney	1 year
Secondary	To compare the lesions identified in [18F]BL40 and [18F]FDG	Scan features for comparison may include, but are not limited to: Site of lesions	1 year
Secondary	To assess reader confidence	Diagnostic confidence on a three-point scale (high, moderate and low)	1 year